

# JoAnne McLaurin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5950631/publications.pdf>

Version: 2024-02-01

69  
papers

6,559  
citations

94433

37  
h-index

98798

67  
g-index

77  
all docs

77  
docs citations

77  
times ranked

6981  
citing authors

#	ARTICLE	IF	CITATIONS
1	A $\beta$ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. <i>Nature</i> , 2000, 408, 979-982.	27.8	1,472
2	Cyclohexanehexol inhibitors of A $\beta$ aggregation prevent and reverse Alzheimer phenotype in a mouse model. <i>Nature Medicine</i> , 2006, 12, 801-808.	30.7	342
3	Selective targeting of perivascular macrophages for clearance of $\beta$ -amyloid in cerebral amyloid angiopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1261-1266.	7.1	323
4	Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid- $\beta$ Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e10549.	2.5	319
5	Membrane Disruption by Alzheimer $\beta$ -Amyloid Peptides Mediated through Specific Binding to Either Phospholipids or Gangliosides. <i>Journal of Biological Chemistry</i> , 1996, 271, 26482-26489.	3.4	307
6	Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid $\beta$ Peptide and Inhibit A $\beta$ -induced Toxicity. <i>Journal of Biological Chemistry</i> , 2000, 275, 18495-18502.	3.4	240
7	Interactions of Alzheimer amyloid- $\beta$ peptides with glycosaminoglycans. <i>FEBS Journal</i> , 1999, 266, 1101-1110.	0.2	237
8	Amyloid- $\beta$ Peptide Assembly: A Critical Step in Fibrillogenesis and Membrane Disruption. <i>Biophysical Journal</i> , 2001, 80, 1359-1371.	0.5	231
9	Characterization of the Interactions of Alzheimer beta-Amyloid Peptides with Phospholipid Membranes. <i>FEBS Journal</i> , 1997, 245, 355-363.	0.2	189
10	A $\beta$ 42-Peptide Assembly on Lipid Bilayers. <i>Journal of Molecular Biology</i> , 2002, 318, 97-107.	4.2	183
11	Structural Transitions Associated with the Interaction of Alzheimer $\beta$ -Amyloid Peptides with Gangliosides. <i>Journal of Biological Chemistry</i> , 1998, 273, 4506-4515.	3.4	173
12	The role of the immune system in Alzheimer disease: Etiology and treatment. <i>Ageing Research Reviews</i> , 2017, 40, 84-94.	10.9	167
13	Amyloid- $\beta$ -dependent compromise of microvascular structure and function in a model of Alzheimer's disease. <i>Brain</i> , 2012, 135, 3039-3050.	7.6	134
14	Examining the zinc binding site of the amyloid- $\beta$ peptide. <i>FEBS Journal</i> , 2000, 267, 6692-6698.	0.2	117
15	Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. <i>Journal of Molecular Medicine</i> , 2007, 85, 603-611.	3.9	114
16	Amyloid- $\beta$ fibrillogenesis: Structural insight and therapeutic intervention. <i>Experimental Neurology</i> , 2010, 223, 311-321.	4.1	113
17	Small molecule inhibitors of A $\beta$ aggregation and neurotoxicity. <i>Drug Development Research</i> , 2009, 70, 111-124.	2.9	93
18	Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. <i>Neurobiology of Aging</i> , 2012, 33, 555-563.	3.1	92

#	ARTICLE	IF	CITATIONS
19	Cellular Membrane Composition Defines A $\beta$ -Lipid Interactions. <i>Journal of Biological Chemistry</i> , 2001, 276, 33561-33568.	3.4	90
20	Early neurovascular dysfunction in a transgenic rat model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 46427.	3.3	83
21	Effect of amino-acid substitutions on Alzheimer's amyloid- $\beta$ peptide-glycosaminoglycan interactions. <i>FEBS Journal</i> , 2000, 267, 6353-6361.	0.2	79
22	Amyloid- $\beta$ Interactions with Chondroitin Sulfate-derived Monosaccharides and Disaccharides. <i>Journal of Biological Chemistry</i> , 2001, 276, 6412-6419.	3.4	70
23	Phenotypic and functional changes in glial cells as a function of age. <i>Neurobiology of Aging</i> , 2002, 23, 105-115.	3.1	69
24	Early-stage attenuation of phase-amplitude coupling in the hippocampus and medial prefrontal cortex in a transgenic rat model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2018, 144, 669-679.	3.9	69
25	Venular degeneration leads to vascular dysfunction in a transgenic model of Alzheimer's disease. <i>Brain</i> , 2015, 138, 1046-1058.	7.6	65
26	Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7177-7184.	3.0	64
27	Reduced Tissue Levels of Noradrenaline Are Associated with Behavioral Phenotypes of the TgCRND8 Mouse Model of Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2012, 37, 1934-1944.	5.4	62
28	Hippocampal GABAergic Neurons are Susceptible to Amyloid- $\beta$ Toxicity in vitro and are Decreased in Number in the Alzheimer's Disease TgCRND8 Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 293-308.	2.6	61
29	scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer's Disease. <i>Advances in Pharmacology</i> , 2012, 64, 177-212.	2.0	61
30	Contribution of simple saccharides to the stabilization of amyloid structure. <i>Biochemical and Biophysical Research Communications</i> , 2005, 328, 1067-1072.	2.1	55
31	Small molecule amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2010, 31, 203-213.	2.6	53
32	Interaction of human and mouse A $\beta$ peptides. <i>Journal of Neurochemistry</i> , 2004, 91, 1398-1403.	3.9	51
33	$\beta$ -Melanocyte Stimulating Hormone Prevents GABAergic Neuronal Loss and Improves Cognitive Function in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2014, 34, 6736-6745.	3.6	48
34	Neurovascular unit remodelling in the subacute stage of stroke recovery. <i>NeuroImage</i> , 2017, 146, 869-882.	4.2	45
35	A sulfated proteoglycan aggregation factor mediates amyloid- $\beta$ peptide fibril formation and neurotoxicity. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1999, 6, 233-243.	3.0	43
36	Modulation of amyloid- $\beta$ aggregation and toxicity by inositol stereoisomers. <i>FEBS Journal</i> , 2008, 275, 1663-1674.	4.7	43

#	ARTICLE	IF	CITATIONS
37	Amyloid $\beta$ -protein ( $A\beta$ ) associated with lipid molecules: immunoreactivity distinct from that of soluble $A\beta$ . FEBS Letters, 1997, 420, 43-46.	2.8	42
38	Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1629-1637.	3.8	41
39	Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid- $\beta$ attenuation. Brain, 2020, 143, 359-373.	7.6	41
40	Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. ELife, 2015, 4, .	6.0	38
41	Sodium/myo-Inositol Transporters: Substrate Transport Requirements and Regional Brain Expression in the TgCRND8 Mouse Model of Amyloid Pathology. PLoS ONE, 2011, 6, e24032.	2.5	34
42	PPAR- $\alpha$ Expression Inversely Correlates with Inflammatory Cytokines IL-1 $\beta$ and TNF- $\alpha$ in Aging Rats. Neurochemical Research, 2005, 30, 1369-1375.	3.3	32
43	Reduced oligomeric and vascular amyloid- $\beta$ following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vaccine, 2009, 27, 1365-1376.	3.8	28
44	Investigating the efficacy of a combination $A\beta$ -targeted treatment in a mouse model of Alzheimer's disease. Brain Research, 2018, 1678, 138-145.	2.2	28
45	Immunotherapy as treatment for Alzheimer's disease. Expert Review of Neurotherapeutics, 2007, 7, 1535-1548.	2.8	27
46	Interaction between therapeutic interventions for Alzheimer's disease and physiological $A\beta$ clearance mechanisms. Frontiers in Aging Neuroscience, 2015, 7, 64.	3.4	26
47	$\alpha$ -Synuclein aggregation, seeding and inhibition by scyllo-inositol. Biochemical and Biophysical Research Communications, 2016, 469, 529-534.	2.1	25
48	Rho-associated protein kinases as therapeutic targets for both vascular and parenchymal pathologies in Alzheimer's disease. Journal of Neurochemistry, 2018, 144, 659-668.	3.9	24
49	Immunization with amyloid- $\beta$ using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiology of Disease, 2006, 23, 433-444.	4.4	20
50	Impaired Cholinergic Excitation of Prefrontal Attention Circuitry in the TgCRND8 Model of Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 12779-12791.	3.6	18
51	Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chemical Communications, 2009, , 5527.	4.1	17
52	Region-specific distribution of $\beta$ -amyloid peptide and cytokine expression in TgCRND8 mice. Neuroscience Letters, 2011, 492, 5-10.	2.1	16
53	In Vivo Uptake of $\beta$ -Amyloid by Non-Plaque Associated Microglia. Current Alzheimer Research, 2012, 9, 890-901.	1.4	15
54	Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. Brain Research, 2005, 1034, 139-146.	2.2	13

#	ARTICLE	IF	CITATIONS
55	Reactive astrocytes associated with plaques in TgCRND8 mouse brain and in human Alzheimer brain express phosphoprotein enriched in astrocytes (PEA $\alpha$ 15). FEBS Letters, 2013, 587, 2448-2454.	2.8	13
56	scyllo-Inositol Promotes Robust Mutant Huntingtin Protein Degradation. Journal of Biological Chemistry, 2014, 289, 3666-3676.	3.4	13
57	Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's disease. Translational Neurodegeneration, 2022, 11, 26.	8.0	13
58	Biophysical characterization of longer forms of amyloid beta peptides: possible contribution to flocculent plaque formation. Journal of Neurochemistry, 2005, 95, 1667-1676.	3.9	12
59	Combinatorial Treatment Using Umbilical Cord Perivascular Cells and A $\beta$ Clearance Rescues Vascular Function Following Transient Hypertension in a Rat Model of Alzheimer Disease. Hypertension, 2019, 74, 1041-1051.	2.7	11
60	Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models. European Journal of Neuroscience, 2013, 37, 1994-2004.	2.6	10
61	Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics. CNS and Neurological Disorders, 2005, 4, 553-567.	4.3	9
62	Effects of Neurotrophic Support and Amyloid-Targeted Combined Therapy on Adult Hippocampal Neurogenesis in a Transgenic Model of Alzheimer's Disease. PLoS ONE, 2016, 11, e0165393.	2.5	8
63	Refining an Alzheimer's vaccine to avoid an inflammatory response. Expert Opinion on Biological Therapy, 2005, 5, 809-816.	3.1	7
64	The effects of voluntary running on cerebrovascular morphology and spatial short-term memory in a mouse model of amyloidosis. NeuroImage, 2020, 222, 117269.	4.2	6
65	Cerebrovascular damage after midlife transient hypertension in non-transgenic and Alzheimer's disease rats. Brain Research, 2021, 1758, 147369.	2.2	6
66	Chapter 5. scyllo-Inositol: A Potential Therapeutic for Alzheimer's Disease. RSC Drug Discovery Series, 2010, , 94-116.	0.3	2
67	Covert strokes prior to Alzheimer's disease onset accelerate peri-lesional pathology but not cognitive deficits in an inducible APP mouse model. Brain Research, 2021, 1754, 147233.	2.2	2
68	Effects of voluntary exercise on cognition, neurogenesis, and plaque load in a mouse model of Alzheimers disease.. FASEB Journal, 2013, 27, 712.33.	0.5	0
69	Adult hippocampal neurogenesis: Another target of scylloinositol treatment?. FASEB Journal, 2013, 27, 316.3.	0.5	0